血液科医生对CAR-T细胞疗法试验筛查与招募患者的障碍与促进因素:理论指导的访谈研究
本研究在加拿大开展首个CAR-T细胞疗法试验前,基于理论域框架访谈15名血液科医生,识别其筛查和招募患者参与早期免疫疗法试验的障碍与促进因素。医生表达「谨慎希望」,多数有意筛查但担忧安全性、可行性和筛查标准,并指出资源、工作负荷、遗忘和患者等待时间等实践障碍。研究展示了该框架在识别试验招募障碍方面的价值。
要点
- 15名血液科医生中14名有意筛查CAR-T试验,但存在安全性、可行性和筛查标准担忧。
- 资源、工作负荷、遗忘和患者等待时间被识别为筛查的关键实践障碍。
- 角色和流程的变异性可能导致遗漏试验候选人。
核心结论
- 基于理论域框架的访谈可识别血液科医生筛查和招募CAR-T试验患者的障碍与促进因素。
- 医生表达「谨慎希望」,多数有意筛查但存在安全性和可行性担忧。
- 未解决的障碍可能削弱试验招募。
研究设计与样本
- 对加拿大血液科医生进行访谈研究,采用定向内容分析识别相关理论域。
- 共访谈15名血液科医生。
主要发现
- 15名医生中14名有意筛查试验(涉及知识、目标、后果信念、意图域)。
- 实践障碍包括资源、工作负荷、遗忘和患者等待CAR-T细胞时间(涉及环境背景与资源、记忆注意与决策、行为调节域)。
- 角色和流程变异性可能导致遗漏试验候选人(涉及社会与专业角色域)。
临床怎么用
- 可针对资源、工作负荷和流程变异等障碍优化试验程序。
- 使用理论域框架识别招募障碍可 inform 未来早期癌症疗法试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel therapies often fail to reach the bedside due to low trial recruitment rates. Prior to conducting one of the first chimeric antigen receptor (CAR) T cell therapy trials in Canada, we used the Theoretical Domains Framework, a novel tool for identifying barriers and enablers to behavior change, to identify physician-related barriers and enablers to screening and recruiting patients for an early phase immunotherapy trial. METHODS: We conducted interviews with hematologists across Canada and used a directed content analysis to identify relevant domains reflecting the key factors that may affect screening and recruitment. RESULTS: In total, we interviewed 15 hematologists. Physicians expressed "cautious hope"; while expressing safety, feasibility, and screening criteria concerns, 14 out of 15 hematologists intended to screen for the trial (domains: knowledge, goals, beliefs about consequences, intentions). Physicians underscored the "challenging contexts," identifying resources, workload, forgetting, and patient wait times to receive CAR T cells as key practical barriers to screening (domains: environmental context and resources, memory, attention and decision-making, behavioral regulation). They also highlighted "variability in roles and procedures" that may lead to missed trial candidates (domain: social and professional role). Left unaddressed, these barriers may undermine trial recruitment. CONCLUSIONS: This study is among the first to use the Theoretical Domains Framework from the physician perspective to identify recruitment challenges to early phase trials and demonstrates the value of this approach for identifying barriers to screening and recruitment that may not otherwise have been elicited. This approach can optimize trial procedures and may serve to inform future promising early phase cancer therapy trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03765177 . Registered on December 5, 2018.
引用
- Castillo G, Lalu M, Asad S, et al. Hematologists' barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study. Trials. 2021. PMID: 33766105. doi:10.1186/s13063-021-05121-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。